medigraphic.com
Colegio de Medicina Interna de México.

2012, Número 1

<< Anterior Siguiente >>

Med Int Mex 2012; 28 (1)


Tratamiento quirúrgico de la diabetes mellitus tipo 2

Carrillo ER, Arias DCR, Ferrusquía TDL, Peralta PAB, Carrillo CJR

Idioma: Español
Referencias bibliográficas: 56
Paginas: 38-46
Archivo PDF: 320.54 Kb.


RESUMEN

La diabetes mellitus tipo 2 es una enfermedad crónica y progresiva. El tratamiento se ha dirigido a retardar su aparición y disminuir la gravedad de las complicaciones. La cirugía metabólica, una nueva rama de la cirugía bariátrica, ofrece un nuevo horizonte: la remisión completa de la enfermedad. La evidencia científica ha demostrado que ciertas operaciones, en especial la banda gástrica, el bypass gástrico en Y de Roux y la derivación biliopancreática con cruce duodenal, mejoran el metabolismo de la glucosa. Los estudios clínicos en los que se ha evaluado la repercusión de la cirugía metabólica en enfermos con diabetes mellitus tipo 2 han mostrado mejoría en la función de las células B, sensibilidad y secreción de insulina y reducción en la resistencia en relación con los cambios en la cinética de hormonas que influyen en la saciedad y homeostasis de la glucosa, entre las que destacan: leptina, grelina, adiponectina, péptido 1 semejante al glucagón y polipéptido insulinotrópico dependiente de glucosa. Estos procedimientos se han asociado con remisión de la diabetes mellitus tipo 2 y mejor control metabólico de la enfermedad, lo que los hace una buena alternativa para el tratamiento de la diabetes mellitus tipo 2 en pacientes seleccionados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106:329-333.

  2. Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999;84:1165-1171.

  3. Bailey CJ. The challenge of managing coexistent type 2 diabetes and obesity. BMJ 2011;342: 1-8.

  4. Villalpando S, Rojas R, Shamah-Levy T, Avila MA, Gaona B, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Pública Méx 2010;52:19-26.

  5. National Institutes of Health. Successful diet and exercise therapy is conducted in Vermont for ‘‘diabesity’’. JAMA 1980;243:519-520.

  6. Astrup A, Finer N. Redefining type 2 diabetes: “diabesity” or “obesity dependent diabetes mellitus”? Obes Rev 2000;1:57-59.

  7. Hamnvik OP, McMahon GT. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med 2009; 76: 234-243.

  8. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31:2086-2091.

  9. Scheen A.J. Current management of coexisting obesity and type 2 diabetes Drugs 2003 ; 63 : 1165-1184.

  10. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32:805-822.

  11. Scheen A.J. Aggressive weight reduction treatment in the management of type 2 diabetes Diab Metab 1998;23:116-123.

  12. Pories WJ, MacDonald KG, Flickinger EG, Dohm GL, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992;215:633-643.

  13. Pories WJ, Swanson MS, MacDonald KG, Long SB, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-352.

  14. Schernthaner G, Morton JM. Bariatric surgery in patients with morbid obesity and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S297-S302.

  15. Schulman AP, Del Genio F, Sinha N, Rubino F. “Metabolic” surgery for the treatment of type 2 diabetes. Endocr Pract 2009;15:624-631.

  16. Pories WJ. Etiology of Type II Diabetes Mellitus: Role of the Foregut. World J Surg 2001;25: 527-531.

  17. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obesity Surgery 2005;15:692-699.

  18. Pories WJ. Bariatric Surgery: Risks and Rewards. J Clin Endocrinol Metab 2008;93:s89-s96.

  19. Purnell JQ, Flum DR. Bariatric Surgery and Diabetes Who Should Be Offered the Option of Remission? JAMA 2009;301:1593-1595.

  20. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009;52:2270-2276.

  21. Crookes PF. Surgical treatment of morbid obesity. Annu Rev Med 2006;57:243-264.

  22. Brancatisano A, Wahlroos S, Matthews S, Brancatisano R. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis 2008;4:423-429.

  23. Schauer PR, Burguera B, Ikramuddin S, Cottam D, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467-485.

  24. Scopinaro N, Papadia F, Camerini G, Marinari G, et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008;18:1035-1038.

  25. Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2009;121:885-893.

  26. Colquitt JL, Picot J, Loveman E, Cleqq AJ. Surgery for obesity. Cochrane Database Syst Rev 2009; 2:1-142.

  27. Rosenthal R, Li X, Samuel S, Martinez P, Zheng C. Effect of sleeve gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis 2009;5:429-434.

  28. Geloneze B, Geloneze SR, Fiori C, Stabe C, et al. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg 2009;19:1077-1083.

  29. DePaula AL, Macedo AL, Mota BR, Schraibman V. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc 2009;23:1313-1320.

  30. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518-2525.

  31. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009;32:514-520.

  32. Letiexhe MR, Desaive C, Lefèbvre PJ, Scheen AJ. Intact cross-talk between insulin secretion and insulin action after post-gastroplasty recovery of ideal body weight in severely obese patients. Int J Obesity 2004;28:821-823.

  33. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995;80:364-369.

  34. Kadera BE, Lum K, Grant J, Pryor AD, et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis 2009;5:305-309.

  35. Buchwald H, Avidor Y, Braunwald E. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA 2004;292:1724-1737.

  36. Mottin CC, Vontobel Padoin A, Schroer CE, Barancelli FT, et al. Behaviour of Type 2 Diabetes Mellitus in Morbid Obese Patients Submitted to Gastric Bypass. Obes Surg 2008;18:179-181.

  37. Yang J, Li C, Liu H, Gu H, et al. Effects of subtotal gastrectomy and roux-en-y gastrojejunostomy on the clinical outcome of type 2 diabetes mellitus. J Surg Res 2010;164: e67-71.

  38. Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit Consensus Conference. Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus. Ann Surg 2010;251: 399-405.

  39. Ferzli GS, Dominique E, Ciaglia M, Bluth MH, et al. Clinical improvement after duodenojejunal bypass for nonobese type 2 diabetes despite minimal improvement in glycaemic homeostasis. World J Surg 2009;33: 972-979.

  40. DeMaria EJ, Winega DA, Pate VW, Hutcher NE, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the bariatric outcomes longitudinal database. Ann Surg 2010;252:559-567.

  41. Lanzarini E, Csendes A, Lembach H, Molina J, Gutiérrez L, Silva J. Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg 2010;34:2098-2102.

  42. Camastra S, Manco M, Mari A, Greco AV, et al. β-Cell function in severely obese type 2 diabetic patients. Long-term effects of bariatric surgery. Diabetes Care 2007;30:1002-1004.

  43. Trakhtenbroit MA, Leichman JG, Algahim MF, Miller CC, et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 2009;122:435-442.

  44. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, Van Loan MD, Ali MR, Wolfe BM. Circulating concentrations of highmolecular- weight adiponectin are increased following Rouxen- Y gastric bypass surgery. Diabetologia 2006;49:2552-2558. Peterli R, lnerhanssen BW, Peters T, Devaux N, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. Ann Surg 2009;250:234-241.

  45. White SA, Kimber R, Veitch PS, Nicholson ML. Surgical treatment of diabetes mellitus by islet cell and pancreas transplantation. Postgrad Med J 2001;77:383-387.

  46. Raikwar SP, Zavazava N. Insulin producing cells derived from embryonic stem cells: are we there yet? J Cell Physiol 2009;218:256-263.

  47. Iozzo P. Viewpoints on the Way to the Consensus Session. Where does insulin resistance start? The adipose tissue. Diabetes Care 2009;32:S168-173.

  48. Santoro S, Prieto Velhote MN, Malzoni CE, Milleo FQ, et al. Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution. Sao Paulo Med J 2006;124:192-197.

  49. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric Banding. International Journal of Obesity. 2002;26:193-199.

  50. Fabbrini E, Tamboli RA, Magkos F, Marks, Shulman PA, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139:448-455.

  51. Scopinaro N, Adami GF, Marinari GM. Biliopancreatic diversion. World J Surg 1998; 22: 936-946.

  52. Noya G, Cossu ML, Coppola M. Biliopancreatic diversion preserving the stomach and pylorus in the treatment of hypercholesterolemia and diabetes type II: results in the first 10 cases. Obes Surg 1998;8 67-72.

  53. Marceau P, Hould FS, Simard S. Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947-954.

  54. Sugerman HJ,Wolfe LG, Sica DA. Diabetes and hypertension in severe obesity and effects of gastric bypass induced weight loss. Ann Surg 2003;237:751-756.

  55. Dolan K, Bryant R, Fielding G. Treating diabetes in the morbidly obese by laparoscopic gastric banding. Obesity Surgery 2003;13:439-443.

  56. Marinari GM, Papadia FS, Briatore L, Adami G, Scopinaro N. Type 2 diabetes and weight loss following biliopancreatic diversion for obesity. Obesity Surgery 2006;16:1440-1444.




2020     |     www.medigraphic.com